OncoMatch/Clinical Trials/NCT07025005
Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
Is NCT07025005 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet and Bortezomib + Lenalidomide + Dexamethasone for peripheral neuropathy.
Treatment: Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet · Bortezomib + Lenalidomide + Dexamethasone — This study aims at evaluating the possible beneficial role of Fenofibrate in attenuating the peripheral neuropathy associated with bortezomib (velcade), lenalidomide (revlimid), and dexamethasone (VRd) regimen in newly diagnosed multiple myeloma patients.The study aims to asses VRd protocol induced peripheral neuropathy through: 1. The implication of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 5, 2017) and The use of Neurotoxicity-12 items questionnaire score (Ntx-12) from the validated Functional Assessment of Cancer Therapy/Gynecologic Oncology Group "FACT/GOG-Ntx-12 for grading of neuropathy at baseline and by the end of every two VRd cycles. 2. The assessment of biological markers: Brain -derived neurotrophic factor (BDNF) and Neuro-filament light chain (NfL). through comparing two groups: Group one: (Control group; n=22): which will receive 6 cycles of VRd regimen (each cycle will be given every 28 days). Group two: (Fenofibrate group; n=22): which will receive the same regimen plus Fenofibrate 160 mg once daily.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: neurotoxic agent (cis-platin, vincristine, taxanes, foscarnet, isoniazid)
prior exposure to neurotoxic agents (Cis-platin, vincristine, taxanes, foscarnet, INH, etc..) in the last 6 months
Lab requirements
Blood counts
absolute neutrophilic count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L, hemoglobin level ≥ 10 g/dl
Kidney function
serum creatinine < 1.5 mg/dl
Liver function
serum bilirubin < 1.2 mg/dl
Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L and hemoglobin level ≥ 10 g/dl). Patients with adequate liver function (serum bilirubin < 1.2 mg/dl) and adequate renal function (serum creatinine < 1.5 mg/d).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify